Track Aquestive Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Aquestive Therapeutics, Inc. AQST Open Aquestive Therapeutics, Inc. in new tab

4.14 USD
EPS
-0.78
P/B
-15.14
Beta
1.50
Target Price
8.89 USD
Aquestive Therapeutics, Inc. logo

Aquestive Therapeutics, Inc.

🧾 Earnings Recap – Q3 2025

Aquestive Therapeutics demonstrated strong momentum heading into its Q3 2025 earnings, highlighted by increased awareness of its Anaphylm dibutepinephrine Sublingual Film program and preparations for a potential FDA approval.

  • Nearly 25% of allergists have engaged with Aquestive's CME training, enhancing awareness of Anaphylm ahead of the FDA review due by January 31, 2026.
  • Strategic prelaunch activities for Anaphylm are on track, with marketing materials finalized and a supply chain ready for rapid production upon FDA approval.
  • Leadership restructuring aims to bolster efforts in both the Anaphylm launch and the Adrenaverse platform, including the appointment of Dr. Matthew Davis as Chief Development Officer.
  • The company anticipates initiating clinical trials for its AQST-108 program in January 2026, further expanding its product pipeline.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 10, 2026
EPS-0.78
Book Value-0.28
Price to Book-15.14
% Insiders3.509%
Growth
Revenue Growth0.10%
Estimates
Forward P/E-7.21
Forward EPS-0.58
Target Mean Price8.89

DCF Valuation

Tweak assumptions to recompute fair value for Aquestive Therapeutics, Inc. (AQST)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Aquestive Therapeutics, Inc. Logo Aquestive Therapeutics, Inc. Analysis (AQST)

United States Health Care Official Website Stock

Is Aquestive Therapeutics, Inc. a good investment? Aquestive Therapeutics, Inc. (AQST) is currently trading at 4.14 USD. Market analysts have a consensus price target of 8.89 USD. This suggests a potential upside from current levels.

Earnings Schedule: Aquestive Therapeutics, Inc. is expected to release its next earnings report on Aug. 10, 2026. The market consensus estimate for Forward EPS is -0.58.

Investor FAQ

Does Aquestive Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Aquestive Therapeutics, Inc.?

Aquestive Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 10, 2026. The company currently has a trailing EPS of -0.78.

Company Profile

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Exchange Ticker
NMS (United States) AQST

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion